

Senate File 2123

H-8284

1 Amend Senate File 2123, as passed by the Senate, as
2 follows:

3 1. Page 1, before line 1 by inserting:

4 <Section 1. Section 124.201, subsection 4, Code
5 2011, is amended to read as follows:

6 4. If any new substance is designated as a
7 controlled substance under federal law and notice of
8 the designation is given to the board, the board shall
9 similarly designate as controlled the new substance
10 under this chapter after the expiration of thirty days
11 from publication in the Federal Register of a final
12 order designating a new substance as a controlled
13 substance, unless within that thirty-day period the
14 board objects to the new designation. In that case
15 the board shall publish the reasons for objection
16 and afford all interested parties an opportunity
17 to be heard. At the conclusion of the hearing the
18 board shall announce its decision. Upon publication
19 of objection to a new substance being designated
20 as a controlled substance under this chapter by the
21 board, control under this chapter is stayed until
22 the board publishes its decision. If a substance
23 is designated as controlled by the board under this
24 paragraph subsection the control shall be temporary and
25 if within sixty days after the next regular session
26 of the general assembly convenes it has not made the
27 corresponding changes in this chapter, the temporary
28 designation of control of the substance by the board
29 shall be nullified.

30 Sec. _____. Section 124.204, subsection 4, paragraph
31 ai, Code Supplement 2011, is amended by striking the
32 paragraph and inserting in lieu thereof the following:

33 ai. (1) Salvia divinorum.

34 (2) Salvinorin A.

35 (3) HU-210. [(6aR,10aR)-9-(hydroxymethyl)-6,6-
36 dimethyl-3-(2-methyloctan-2-yl)
37 6a,7,10,10a-tetrahydrobenzo[c] chromen-1-ol)].

38 (4) HU-211(dexanabinol,
39 (6aS,10aS)-9-(hydroxymethyl)-6,6-
40 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
41 chromen-1-ol).

42 (5) Unless specifically exempted or unless
43 listed in another schedule, any material, compound,
44 mixture, or preparation which contains any quantity of
45 cannabimimetic agents, or which contains their salts,
46 isomers, and salts of isomers whenever the existence of
47 such salts, isomers, and salts of isomers is possible
48 within the specific chemical designation.

49 (a) The term "*cannabimimetic agents*" means any
50 substance that is a cannabinoid receptor type 1 (CB1

1 receptor) agonist as demonstrated by binding studies
2 and functional assays within any of the following
3 structural classes:

- 4 (i) 2-(3-hydroxycyclohexyl)phenol with substitution
5 at the 5-position of the phenolic ring by alkyl or
6 alkenyl, whether or not substituted on the cyclohexyl
7 ring to any extent.
- 8 (ii) 3-(1-naphthoyl)indole or
9 3-(1-naphthylmethane)indole by substitution at the
10 nitrogen atom of the indole ring, whether or not
11 further substituted on the indole ring to any extent,
12 whether or not substituted on the naphthoyl or naphthyl
13 ring to any extent.
- 14 (iii) 3-(1-naphthoyl)pyrrole by substitution at
15 the nitrogen atom of the pyrrole ring, whether or not
16 further substituted in the pyrrole ring to any extent,
17 whether or not substituted on the naphthoyl ring to any
18 extent.
- 19 (iv) 1-(1-naphthylmethylene)indene by substitution
20 of the 3-position of the indene ring, whether or not
21 further substituted in the indene ring to any extent,
22 whether or not substituted on the naphthyl ring to any
23 extent.
- 24 (v) 3-phenylacetylindole or 3-benzoylindole by
25 substitution at the nitrogen atom of the indole ring,
26 whether or not further substituted in the indole ring
27 to any extent, whether or not substituted on the phenyl
28 ring to any extent.

29 (b) Such terms include:

- 30 (i) CP 47, 497 and homologues 2-[(1R, 3S)-3-
31 hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol).
- 32 (ii) JWH-018 and AM678
33 1-Pentyl-3-(1-naphthoyl)indole.
- 34 (iii) JWH-073 1-Butyl-3-(1-naphthoyl)indole.
- 35 (iv) JWH-200
36 [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-
37 naphthalenyl-methanone.
- 38 (v) JWH-19 1-hexyl-3-(1-naphthoyl)indole.
- 39 (vi) JWH-81
40 1-pentyl-3-[1-(4-methoxynaphthoyl)]indole.
- 41 (vii) JWH-122
42 1-pentyl-3-(4-methyl-1-naphthoyl)indole.
- 43 (viii) JWH-250
44 1-pentyl-3-(2-methoxynaphthoyl)indole.
- 45 (ix) RCS-4 and SR-19
46 1-pentyl-3-[(4methoxy)-benzoyl]indole.
- 47 (x) RCS-8 and SR-18 1-cyclohexylethyl-3-
48 (-2-methoxyphenylacety)indole.
- 49 (xi) AM2201
50 1-(5-fluoropentyl)-3-(1-naphthoyl)indole.

1 (xii) JWH-203
2 1-pentyl-3-(2-chlorophenylacetyl)indole.
3 (xiii) JWH-398
4 1-pentyl-3-(4-chloro-1-naphthoyl)indole.
5 (xiv) AM694
6 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole.
7 (xv) Cannabicyclohexanol or CP-47,497 C8-homolog
8 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol.
9 Sec. ____ . Section 124.204, subsection 6, Code
10 Supplement 2011, is amended by adding the following new
11 paragraph:
12 NEW PARAGRAPH. *i.* Any substance, compound,
13 mixture or preparation which contains any quantity
14 of any synthetic cathinone that is not approved as
15 a pharmaceutical, including but not limited to the
16 following:
17 (1) Mephedrone, also known as
18 4-methylmethcathinone, (RS)-2-
19 methylamino-1-(4-methylphenyl) propan-1-one.
20 (2) Methylene-dioxypyrovalerone (MDPV) [(1-(1,3-
21 Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone].
22 (3) Methylone, also known as
23 3,4-methylenedioxy-methcathinone.
24 (4) Naphthylpyrovalerone (naphyrone).
25 (5) 4-fluoromethcathinone (flephedrone) or a
26 positional isomer of 4-fluoromethcathinone.
27 (6) 4-methoxymethcathinone (methedrone; Bk-PMMA).
28 (7) Ethcathinone.
29 (8) 3,4-methylenedioxyethcathinone (ethylone).
30 (9) Beta-keto-N-methyl-3,4-benzodioxolybutanamine
31 (butylone).
32 (10) N,N-dimethylcathinone (metamfepramone).
33 (11) Alpha-pyrrolidinopropiophenone (alpha-PPP).
34 (12) 4-methoxy-alpha-pyrrolidinopropiophenone
35 (MOPPP).
36 (13) 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone
37 (MDPPP).
38 (14) Alpha-pyrrolidinovalerophenone (alpha-PVP).
39 (15) 6,7-dihydro-5H-indeno(5,6-d)-1,3-dioxal-6
40 6-amine) (MDAI).
41 (16) 3-fluoromethcathinone.
42 (17) 4'-Methyl-2-pyrrolidinobutiophenone (MPBP).
43 (18) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine
44 (2C-E).
45 (19) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine
46 (2C-D).
47 (20) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine
48 (2C-C).
49 (21) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine
50 (2C-I).

1 (22) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine
2 (2C-T-2).
3 (23) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine
4 (2C-T-4).
5 (24) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H).
6 (25) 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine
7 (2C-N).
8 (26) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine
9 (2C-P).>
10 2. Page 1, after line 23 by inserting:
11 <Sec. _____. Section 124.401, subsection 1, paragraph
12 d, Code Supplement 2011, is amended to read as follows:
13 d. Violation of this subsection, with respect
14 to any other controlled substances, counterfeit
15 substances, or simulated controlled substances
16 classified in section 124.204, subsection 4, paragraph
17 "ai", section 124.204, subsection 6, paragraph "i",
18 or classified in schedule IV or V is an aggravated
19 misdemeanor. However, violation of this subsection
20 involving fifty kilograms or less of marijuana or
21 involving flunitrazepam is a class "D" felony.>
22 3. Page 1, after line 26 by inserting:
23 <Sec. _____. EFFECTIVE UPON ENACTMENT. The following
24 provisions of this Act, being deemed of immediate
25 importance, take effect upon enactment:
26 1. The section of this Act amending section
27 124.201, subsection 4.
28 2. The section of this Act amending section
29 124.204, subsection 4, paragraph "ai".
30 3. The section of this Act amending section
31 124.204, subsection 6.
32 4. The section of this Act amending section
33 124.401, subsection 1, paragraph "d".>
34 4. Title page, line 2, by striking <applicable> and
35 inserting <applicable, and including effective date
36 provisions>

FRY of Clarke